SCHEMBL1543657

SCHEMBL1543657

N#CC1(C(=O)N2CCOCC2)CCCC(N(Cc2ccccc2)Cc2ccccc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
FKBP1A P62942 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CTSS P25774 5/20 0.39
CCR5 P51681 1/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TSHR P16473 2/20 0.37
RECQL P46063 1/20 0.37
CNR1 P21554 1/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543248 0.88 CCR5 (0.41) CCR5MEN1KMT2AALDH1A1USP30
SCHEMBL1543430 0.87 HSD11B1 (0.44) SMN1; SMN2CCR5MEN1KMT2ATSHR
SCHEMBL1543234 0.82 MEN1 (0.40) CTSSCCR5MEN1KMT2ANPSR1
SCHEMBL1543586 0.78 MAPK1 (0.38) CTSSCCR5MEN1KMT2ANPSR1
SCHEMBL1543068 0.77 POLB (0.42) SMN1; SMN2CCR5MEN1KMT2ARECQL
SCHEMBL1543170 0.73 MAPK1 (0.38) SMN1; SMN2SLC6A2SLC6A4SLC6A3CTSS
SCHEMBL19583039 0.68 CCR5 (0.44) SLC6A2SLC6A4CCR5MEN1KMT2A
SCHEMBL31732922 0.67 GAA (0.46) SMN1; SMN2CTSSMEN1KMT2ANPSR1
SCHEMBL1543700 0.67 KDM4E (0.41) CCR5MEN1KMT2ANPSR1ALDH1A1
SCHEMBL13735232 0.66 KDM4E (0.46) SLC6A2SLC6A4SLC6A3CCR5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307377-A1 NICOTINAMIDE DERIVATIVES Pfizer Limited (GB) 2011-04-13 EP disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
US-20100173888-A1 Nicotinamide Derivatives PFIZER INC 2010-07-08 US disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed
WO-2009153720-A1 NICOTINAMIDE DERIVATIVES PFIZER LIMITED (GB) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173888-A1 Nicotinamide Derivatives NNT, NAMPT, NQO1 SMN1; SMN2 1659/4885FKBP1A 2540/4885SLC6A2 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.